— Up to 6 winners are eligible for up to $3 million in seed funding, incubator space,$1 million in total equity for discovery services from Alloy Therapeutics, and expert mentorship —

-多达6位获奖者有资格获得高达300万美元的种子基金、孵化器空间、100万美元的Alloy Therapeutics发现服务总股本以及专家指导-

CAMBRIDGE, Mass., May 1, 2024 /PRNewswire/ -- Mission BioCapital (MBC), in partnership with founding sponsors Eli Lilly and Company (Lilly) and Ono Venture Investment (OVI) and our newest sponsor, Alloy Therapeutics, announced today that applications are open internationally for the 2024 Platinum Program.

马萨诸塞州剑桥市，2024年5月1日/PRNewswire/--Mission BioCapital（MBC）与创始赞助商礼来公司（礼来）和小野风险投资（OVI）以及我们的最新赞助商Alloy Therapeutics合作，今天宣布2024白金计划的申请在国际上开放。

MBC's Platinum Program aims to advance high-potential life sciences start-up companies through funding, global laboratory space, expert mentorship, and discovery services to accelerate their launch and initial development. Early-stage biotechnology innovators from around the globe are invited to apply.

MBC的白金计划旨在通过资金、全球实验室空间、专家指导和发现服务来推动极具潜力的生命科学初创公司，以加速其启动和初步开发。邀请来自全球的早期生物技术创新者申请。

Applications will be open through the middle of July, and winners will be announced in Fall 2024..

申请将于7月中旬开放，获奖者将于2024年秋季公布。。

The 2024 Platinum Program will award each of up to six winning start-ups with:

2024白金计划将授予六家获奖初创公司：

A guaranteed lab bench in one of MBC's affiliated incubators located in 13 cities in the U.S. and Europe

位于美国和欧洲13个城市的MBC附属孵化器之一的实验室长凳

Up to $500,000 of seed capital provided as a SAFE investment

高达50万美元的种子资本作为安全投资提供

Drug discovery services from Alloy Therapeutics to enable companies with a derisked path to lead candidate

来自Alloy Therapeutics的药物发现服务，使公司能够通过嘲弄的途径领导候选人

Strategic scientific and business development mentorship from experts at Lilly, OVI, Alloy Therapeutics, MBC, and other companies across MBC's corporate network

礼来、OVI、Alloy Therapeutics、MBC和MBC企业网络中其他公司的专家提供战略科学和业务发展指导

'Since its establishment two years ago, our Platinum Program has awarded eight high-potential, early-stage founders with a total of $3.5 million in seed funding, lab bench space, and business and scientific mentorship to accelerate the launch and initial development of potentially game-changing innovations,' said Jennifer Griffin, Ph.D., Partner, Mission BioCapital.

Mission BioCapital合伙人詹妮弗·格里芬（JenniferGriffin）博士说：“自两年前成立以来，我们的白金计划已经授予了八位极具潜力的早期创始人，总计350万美元的种子资金、实验室工作台空间以及商业和科学指导，以加速潜在的改变游戏规则的创新的启动和初步开发。”。

'We are looking forward to this year's applicants and encourage early-stage biotechnology innovators from around the globe to apply.'.

“我们期待着今年的申请人，并鼓励来自全球的早期生物技术创新者申请。”。

Winners of MBC's pilot 2022 Platinum Program are developing technologies that include a novel drug development approach that targets genome packaging states known to cause hard-to-treat cancers and other diseases (Tipping Point Biosciences, San Francisco, CA); and development of next-generation therapeutics by combining synthetic biology and machine learning to control cellular stress responses (Integrated Biosciences, San Carlos, CA).

MBC 2022白金计划试点项目的获胜者正在开发技术，其中包括一种新的药物开发方法，该方法针对已知会导致难以治疗的癌症和其他疾病的基因组包装状态（Tipping Point Biosciences，San Francisco，CA）；并通过结合合成生物学和机器学习来控制细胞应激反应来开发下一代疗法（Integrated Biosciences，San Carlos，CA）。

The six winners of the 2023 Platinum Program are currently incubating in San Francisco; Cambridge, MA; New Haven, CT; and Heidelberg, Germany..

2023白金计划的六位获奖者目前正在旧金山孵化；马萨诸塞州剑桥；康涅狄格州纽黑文；和德国海德堡。。

'As the Mission BioCapital Platinum Program enters its third year, we are very pleased to continue our partnership with Lilly and OVI and to welcome our newest partner, Alloy Therapeutics, which will provide a total of up to $1 million of customized antibody services to this year's applicable winners,' said Steve Tregay, Ph.D., Managing General Partner, Mission BioCapital.

Mission BioCapital管理普通合伙人Steve Tregay博士说：“随着Mission BioCapital白金计划进入第三年，我们非常高兴继续与礼来和OVI合作，并欢迎我们的最新合作伙伴Alloy Therapeutics，该公司将为今年的适用获奖者提供总计高达100万美元的定制抗体服务。”。

'By making company formation and early-stage development easier, regardless of geographical origin, our Platinum Program aims to empower and accelerate biotechnology innovation around the globe to improve human health.'.

“通过使公司组建和早期发展更容易，无论其地理来源如何，我们的白金计划旨在增强和加速全球生物技术创新，以改善人类健康。”。

'We are committed to enabling the biotech ecosystem by catalyzing breakthrough science,' said Katie Hewitt, Global Head of Business Development, Lilly Catalyze360. 'The MBC Platinum Program is aligned with Lilly's initiatives to foster and support innovative, early-stage science irrespective of where it originates, and we are delighted to continue our participation in Mission BioCapital's Platinum Program in 2024, helping early-stage scientists and founders cultivate the seeds of biotech innovation.'.

礼来催化360全球业务发展负责人凯蒂·休伊特（KatieHewitt）说，我们致力于通过催化突破性科学来实现生物技术生态系统MBC白金计划与礼来公司旨在促进和支持创新的早期科学的举措保持一致，无论其起源于何处，我们很高兴在2024年继续参与Mission BioCapital的白金计划，帮助早期科学家和创始人培育生物技术创新的种子。”。

'We are excited to see what types of new innovations will be submitted by talented innovators around the globe through the 2024 Platinum Program,' said Shunichiro Matsumoto, Executive Vice President of OVI. 'We look forward to our continued involvement to help identify and enable the next generation of biotechnology leaders.'.

OVI执行副总裁松本俊一郎（ShunichiroMatsumoto）说，我们很高兴看到全球有才能的创新者将通过2024白金计划提交哪些类型的新创新我们期待着我们的继续参与，以帮助识别和培养下一代生物技术领导者。”。

'Part of Alloy's mission is reducing barriers to innovation and increasing access to foundational biologics discovery technologies for company founders, in addition to our collaborations with established biotechnology and pharmaceutical partners,' said Errik Anderson, CEO of Alloy Therapeutics. 'We are enthusiastic about joining the consortium supporting Mission BioCapital's 2024 Platinum Program and excited to begin working with incredible founders to enable their therapeutic programs.'.

Alloy Therapeutics首席执行官埃里克·安德森（Errik Anderson）说：“除了我们与成熟的生物技术和制药合作伙伴的合作外，Alloy的部分使命是减少创新障碍，增加公司创始人获得基础生物制剂发现技术的机会。”我们热衷于加入支持Mission BioCapital 2024白金计划的财团，并很高兴开始与难以置信的创始人合作，以实现他们的治疗计划。”。

To apply, please visit: http://www.missionbiocapital.com/platinumprogram. Only non-confidential information will be required for application.

要申请，请访问：http://www.missionbiocapital.com/platinumprogram.申请只需要非机密信息。

About the Mission BioCapital Platinum ProgramMission BioCapital (MBC) established the Platinum Program in 2022 to enable entrepreneurs with breakthrough technologies from diverse backgrounds to quickly launch new companies. Platinum Program winners receive guaranteed laboratory space at MBC's partner incubators in the U.S.

关于Mission BioCapital白金计划Mission BioCapital（MBC）于2022年建立了白金计划，以使具有突破性技术的企业家能够从不同背景中快速创办新公司。白金计划获奖者在美国MBC合作伙伴孵化器获得有保证的实验室空间。

and Europe, access to world-class experts, lead candidate-enabling drug discovery services, and seed capital to quickly develop scientific data needed to obtain subsequent funding rounds. The program invites innovators from around the world, including academic scientists, to submit breakthrough biomedical innovations that have the potential to advance patient care.

欧洲，获得世界级专家的机会，支持药物发现服务的主要候选人，以及种子资本，以快速开发获得后续资助回合所需的科学数据。该计划邀请世界各地的创新者，包括学术科学家，提交突破性的生物医学创新，这些创新有可能促进患者护理。

In its first two years, the Mission BioCapital Platinum Program has awarded a total of $3.5 million, incubator space, and business mentoring to eight life sciences companies located in two countries and three U.S. states. For more information about the Mission BioCapital Platinum Program, please, visit: http://www.missionbiocapital.com/platinumprogram..

在其头两年中，Mission BioCapital Platinum计划向位于两个国家和三个美国州的八家生命科学公司提供了总计350万美元的资金、孵化器空间和商业指导。有关Mission BioCapital白金计划的更多信息，请访问：http://www.missionbiocapital.com/platinumprogram..

About Mission BioCapitalMission BioCapital is a venture capital firm focused on making pivotal early-stage investments in life sciences companies. We support our portfolio companies through a unique combination of shared lab space, capital investment, and access to strategic partners. With offices in the nation's leading life sciences clusters in Cambridge, MA and San Francisco, Mission BioCapital is dedicated to helping entrepreneurial scientists build successful companies, from idea to exit.

关于Mission BioCapitalMission BioCapital是一家风险投资公司，专注于对生命科学公司进行关键的早期投资。我们通过共享实验室空间、资本投资和获得战略合作伙伴的独特组合来支持我们的投资组合公司。Mission BioCapital在美国领先的生命科学集群（剑桥、马萨诸塞州和旧金山）设有办事处，致力于帮助创业科学家建立成功的公司，从创意到退出。

Learn more at missionbiocapital.com..

更多信息，请访问missionbiocapital.com。。

Contact:Mary MoynihanM2Friend Biocommunications+1 (802) 951-9600mary@m2friend.com

联系人：Mary Moynihanm2 Friend Biocommunications+1（802）951-9600mary@m2friend.com

SOURCE Mission BioCapital

来源Mission BioCapital